FDA issued a draft guidance Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection to help human and animal drug and biologics manufacturers prepare adequate responses to the agency when the manufacturer receives a form 483 at the end of an inspection. The guidance provides recommendations on how to submit a clear and well-organized response to the agency that outlines the manufacturer’s plans to remediate the observations highlighted in the 483 and any other needed corrective and preventive actions.
FDA has found that inadequate or incomplete responses make it difficult for the agency to assess what the manufacturer has corrected and evaluate the manufacturer’s remediation activities. This can delay the agency’s ability to assess the manufacturer’s conformity with current good manufacturing practice requirements.
The agency encourages manufacturers to review the guidance document and provide comments by
May 08, 2026.
